1. Home
  2. EXFY vs AGEN Comparison

EXFY vs AGEN Comparison

Compare EXFY & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.89

Market Cap

156.2M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.35

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
AGEN
Founded
2008
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
147.4M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
EXFY
AGEN
Price
$1.89
$3.35
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.50
$14.50
AVG Volume (30 Days)
2.4M
904.2K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
$142,101,000.00
$42,877,086.00
Revenue This Year
$0.42
$107.63
Revenue Next Year
$0.11
N/A
P/E Ratio
N/A
$3.18
Revenue Growth
2.06
89.95
52 Week Low
$0.69
$2.71
52 Week High
$2.26
$7.04

Technical Indicators

Market Signals
Indicator
EXFY
AGEN
Relative Strength Index (RSI) 67.39 51.47
Support Level $1.37 $2.92
Resistance Level N/A $3.41
Average True Range (ATR) 0.16 0.23
MACD 0.02 0.04
Stochastic Oscillator 85.04 58.33

Price Performance

Historical Comparison
EXFY
AGEN

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: